Con motivo del ‘Encuentro de Alto Nivel One Health sobre Resistencia Antimicrobiana’ –celebrado por la Presidencia española del Consejo de la UE–, Farmaindustria y Veterindustria, que represe...
Read moreThe new facility, located in Cornellà de Llobregat (Barcelona, Spain), which will be fully operational in mid-2024 - will have a surface area of 1,200 m2 and will enhance Bioingenium's capacity for t...
Read moreAbyntek Biopharma, a specialist in providing bioreactive-related integral services, proposes a new high-value solution for genetic analysis.
Read moreEndotype identification from Target-HTN may represent a shift towards targeted, precision-directed therapy for hypertension management in future treatment paradigm
Read moreOryzon Genomics, S.A., a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give ...
Read moreOryzon Genomics, S.A. today announced Last Patient Last Visit in its ongoing Phase IIb PORTICO trial, investigating vafidemstat’s efficacy in Borderline Personality Disorder (BPD). Multiple primary ...
Read moreMineralys Therapeutics today presented data from the Target-HTN Phase 2 trial that further defines an endotype-specific targeted approach for treating uncontrolled or resistant hypertension with lorun...
Read morePeaches Biotech, grupo español de biotecnología especializado en terapias celulares, ha sido galardonado este año como el Proyecto Innovador por el desarrollo de su propia tecnología, basada en el...
Read moreNature Reviews Bioengineering' publishes a collaborative study by the University of Navarra and the University of Paris-Saclay that highlights the significant advance in nanomedicine.
Read moreDC Fine Chemicals ha anunciado hoy su reciente convenio de colaboración con IQS-URL, institución de prestigio en el ámbito educativo y científico. Esta alianza estratégica tiene como objetivo pri...
Read moreEl objetivo es acabar de sufragar el ensayo clínico de su fármaco contra el cáncer de cerebro LAM 561 y «tener fuerza financiera a la hora de negociar con las farmacéuticas» para lanzar el fárm...
Read moreIt has been announced today that the European Commission (EC) has approved EBGLYSS (lebrikizumab) for the treatment of adult and adolescent patients (12 years and older with a bodyweight of at least 4...
Read more